View Older Stories View More Recent Stories

Feb 9, 2023 07:00AM Karyopharm to Present at SVB Securities Global Biopharma Conference
Feb 8, 2023 07:00AM Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
Feb 1, 2023 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 9, 2023 08:00AM Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
Jan 4, 2023 07:00AM Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 12, 2022 07:00AM Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022
Dec 5, 2022 08:30AM Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis
Dec 1, 2022 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 8, 2022 07:00AM Karyopharm to Participate at Upcoming Investor Conferences
Nov 3, 2022 04:05PM Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Nov 3, 2022 09:18AM Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022
Nov 1, 2022 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 1, 2022 07:10AM Karyopharm Therapeutics (KPTI) and Menarini Granted Orphan Medicinal Product Designation in EU for Selixenor
Nov 1, 2022 07:09AM Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
Oct 31, 2022 04:36PM Karyopharm (KPTI) and Menarini Granted Orphan Medicinal Product Designation in EU for Selinexor
Oct 31, 2022 04:35PM Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
Oct 20, 2022 04:05PM Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022
Oct 3, 2022 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2022 07:00AM Karyopharm to Participate at Upcoming Investor Conferences
Sep 1, 2022 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2022 07:30AM Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Aug 2, 2022 07:00AM Karyopharm to Participate at the 2022 Wedbush Pacgrow Healthcare Conference
Aug 1, 2022 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 28, 2022 07:09AM Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022
Jul 21, 2022 09:13AM Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior
Jul 21, 2022 07:06AM Karyopharm Therapeutics (KPTI), Menarini Group Receive Full Marketing Authorisation from EC for NEXPOVIO for Treatment of Patients with MM After at Least One Prior Therapy
Jul 21, 2022 07:00AM Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior
Jul 20, 2022 07:03AM Karyopharm Therapeutics (KPTI) Granted Regulatory Designations for Eltanexor
Jul 20, 2022 07:00AM Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes
Jul 1, 2022 07:00AM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 26, 2022 08:30PM Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
Jun 1, 2022 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 1, 2022 07:00AM Karyopharm to Participate at the Jefferies Healthcare Conference
May 26, 2022 05:08PM Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
May 25, 2022 07:00AM The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study
May 20, 2022 10:39AM Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
May 20, 2022 08:45AM Karyopharm Therapeutics (KPTI) and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO for Treatment of Patients with Refractory MM
May 20, 2022 08:45AM Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
May 12, 2022 11:00AM Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress
May 10, 2022 07:00AM Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
May 5, 2022 07:00AM Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 2, 2022 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 28, 2022 04:05PM Aldeyra Therapeutics Announces Chief Financial Officer Transition
Apr 28, 2022 07:00AM Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
Apr 27, 2022 10:01AM Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting
Apr 7, 2022 07:00AM Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference
Apr 1, 2022 04:05PM Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 29, 2022 08:05AM Karyopharm Therapeutics (KPTI) Appoints Reshma Rangwala as Chief Medical Officer
Mar 29, 2022 08:00AM Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer
View More Recent Stories View Older Stories